Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang 110001, China.
Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang 110001, China.
Pathol Res Pract. 2019 Sep;215(9):152449. doi: 10.1016/j.prp.2019.152449. Epub 2019 Jun 8.
Although increasing evidence has revealed that FOXD2-AS1 overexpression exists in various solid tumors, the value of FOXD2-AS1 as a prognostic marker in such cancers remains uncertain. Accordingly, the present research aimed to assess the association of FOXD2-AS1 with cancer prognosis and predict the biological function of FOXD2-AS1.
We systematically retrieved PubMed, PMC, Web of Science, EMBASE and Wiley Online Library databases for eligible articles published up to December 2018. Pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (95%CIs) were calculated to evaluate the correlation of FOXD2-AS1 expression with overall survival (OS), disease free survival (DFS) and clinicopathological characteristics. We also used five Gene Expression Omnibus (GEO) datasets from breast cancer patients to explore the relationship between FOXD2-AS1 expression and prognosis. Finally, we validated FOXD2-AS1 expression in various carcinomas and predicted its biological function based on the public databases.
A total of 13 studies with 2502 tumor patients were included. The pooled HRs demonstrated that FOXD2-AS1 overexpression was significantly associated with unfavorable OS (HR = 1.39, 95%CI: 1.23-1.57, p < 0.001) and DFS (HR = 2.24, 95%CI: 1.55-3.23, p < 0.001) in tumor patients. The pooled ORs indicated that FOXD2-AS1 upregulation was related to large tumor size (OR = 1.53, 95%CI: 1.26-1.85, p < 0.001), deep invasion depth (OR = 1.99, 95%CI: 1.53-2.58, p < 0.001), distant metastasis (OR = 2.03, 95%CI: 1.69-2.43, p < 0.001) and advanced TNM stage (OR = 1.35, 95%CI: 1.06-1.72, p = 0.0150), but not to lymph node metastasis nor differentiation. Moreover, a similar pooled result for the OS of breast cancer patients was obtained (HR = 1.55, 95%CI: 1.14-2.11, p = 0.0052) by analyzing GEO data. Finally, elevated FOXD2-AS1 expression in various solid tumor tissues was verified based on The Cancer Genome Atlas (TCGA) data. Further functional prediction demonstrated that FOXD2-AS1 may participate in some cancer-related pathways.
Elevated FOXD2-AS1 expression was associated with poor survival in patients with solid tumors and may serve as a potential prognostic biomarker for a variety of cancers.
越来越多的证据表明，FOXD2-AS1 在各种实体瘤中存在过表达，但其作为此类癌症预后标志物的价值仍不确定。因此，本研究旨在评估 FOXD2-AS1 与癌症预后的关联，并预测 FOXD2-AS1 的生物学功能。
我们系统地检索了截至 2018 年 12 月发表的 PubMed、PMC、Web of Science、EMBASE 和 Wiley Online Library 数据库中的合格文章。使用合并风险比（HRs）和优势比（ORs）及其 95%置信区间（95%CI）来评估 FOXD2-AS1 表达与总生存期（OS）、无病生存期（DFS）和临床病理特征的相关性。我们还使用了来自乳腺癌患者的五个基因表达综合（GEO）数据集来探讨 FOXD2-AS1 表达与预后之间的关系。最后，我们在各种癌组织中验证了 FOXD2-AS1 的表达，并基于公共数据库预测了其生物学功能。
共纳入了 13 项包含 2502 例肿瘤患者的研究。合并 HR 表明，FOXD2-AS1 过表达与肿瘤患者的不良 OS（HR=1.39，95%CI：1.23-1.57，p<0.001）和 DFS（HR=2.24，95%CI：1.55-3.23，p<0.001）显著相关。合并 OR 表明，FOXD2-AS1 上调与大肿瘤大小（OR=1.53，95%CI：1.26-1.85，p<0.001）、浸润深度深（OR=1.99，95%CI：1.53-2.58，p<0.001）、远处转移（OR=2.03，95%CI：1.69-2.43，p<0.001）和晚期 TNM 分期（OR=1.35，95%CI：1.06-1.72，p=0.0150）相关，但与淋巴结转移和分化无关。此外，通过分析 GEO 数据，我们在乳腺癌患者的 OS 中获得了相似的合并结果（HR=1.55，95%CI：1.14-2.11，p=0.0052）。最后，我们基于癌症基因组图谱（TCGA）数据验证了各种实体瘤组织中 FOXD2-AS1 表达的升高。进一步的功能预测表明，FOXD2-AS1 可能参与了一些癌症相关途径。
FOXD2-AS1 过表达与实体瘤患者的不良生存相关，可能成为多种癌症的潜在预后标志物。
